GlassScriptPhysician profile
Philip D Ford
NPI 1851451140
$4,406.65
in general payments reported to CMS, 2019-2025
23 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,031 · 2022: $1,209 · 2023: $652 · 2024: $1,026 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,166.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $837.59 | 2021-2025 | Repatha, Tepezza, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $481.77 | 2021-2025 | Relistor, Xifaxan |
| Novo Nordisk INC | $476.51 | 2021-2024 | Wegovy, Saxenda, Rybelsus |
| Abbvie INC. | $435.24 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $258.64 | 2021 | |
| Lilly USA, LLC | $255.35 | 2021-2023 | Mounjaro, Trulicity |
| Genzyme Corporation | $228.92 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.78 | 2021-2023 | Ofev |
| Biohaven Pharmaceutical Holding Company LTD. | $175.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $148.78 | 2022-2023 | Spravato |
| Avanos Medical | $139.10 | 2022 | |
| Neurocrine Biosciences, INC. | $134.36 | 2024 | Ingrezza |
| Biogen, INC. | $110.25 | 2024 | Spinraza |
| Astrazeneca Pharmaceuticals LP | $109.91 | 2022 | |
| Sanofi-Aventis U.S. LLC | $100.00 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $95.30 | 2021-2023 | |
| Hologic Sales and Service, LLC | $70.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $54.95 | 2021-2023 | |
| Glaxosmithkline, LLC. | $27.18 | 2021 | |
| Covis Pharma Gmbh | $20.95 | 2023 | |
| Scilex Pharmaceuticals INC. | $18.11 | 2022 | |
| Merck Sharp & Dohme LLC | $16.21 | 2021 | |
| Sanofi Pasteur INC. | $13.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.